Antibody specificity and off-target testing
Up to a third of all lead candidate antibodies display off-target binding: Read More
De-risk expensive late-stage failures with cost effective early off-target testing during lead selection
Direct antibody binding is quantified on our receptor arrays
Test the binding specificity of 10s to 100s of antibody candidates during your discovery campaign to inform triaging
Only small amounts (50 micrograms) of antibody required
Case Study 1
Camerilzumab (SHR-1210) is an anti-PD1 antibody that has known off-target binding to VEGFR and ULBP2 which were identified on the Ectocellect array. Camrelizumab is formatted as an IgG4.
Case Study 2
An IgG1-formatted anti-PD-L1 antibody was shown to have no detectable off-target binding on the Ectocellect array. As well as the PD-L1 target, the IgG1 antibody Fc receptors were identified.
Essential Features for Reliable Antibody Screening
High-Quality Human Receptor Arrays
Test against validated human receptor ectodomains expressed in human cells, ensuring real-world relevance.
Proactive Off-Target Detection
Identify potential off-target interactions early, minimising costly failures and enhancing clinical trial readiness.
Cost-Effective, Scalable Testing
Our platform provides scalable testing solutions, making it feasible to screen a high number of leads efficiently.
Applications
Boost your research using the Ectocellect receptor array for:
Antibody target deconvolution
Identify the targets of functional antibodies of unknown specificity.
Receptor deorphanisation
Discover new receptors and ligands.
Autoantibody target discovery
Discover the targets of patient autoantibodies.
